Anika Therapeutics (ANIK)
(Delayed Data from NSDQ)
$25.50 USD
+0.14 (0.55%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $25.47 -0.03 (-0.12%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ANIK 25.50 +0.14(0.55%)
Will ANIK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ANIK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANIK
Anika Therapeutics (ANIK) Q2 Earnings Lag Estimates
Philips (PHG) Q1 Earnings Beat Estimates, Revenues Fall Y/Y
ANIK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
Other News for ANIK
Anika Therapeutics Inc (ANIK) Stock Price Up 4.14% on Sep 17
Caligan Partners LP Bolsters Portfolio with Significant Stake in Liquidia Corp
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Politan Provides Update on Why Masimo Shareholders Should Support Urgently Needed Board Change at Company?s 2024 AGM
ANIK Makes Notable Cross Below Critical Moving Average